Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Metabolites|June 23, 2022
FADS Polymorphisms Affect the Clinical and Biochemical Phenotypes of Metabolic SyndromeAleš Žák, Marie Jáchymová, Michal Burda, et al.
The Journal of Nutritional Biochemistry|February 19, 2008
The influence of polymorphism of -493G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stressAles Zák, Marie Jáchymová, Eva Tvrzická, et al.
Nutrition and Cancer|October 16, 2012
Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parametersJaroslav Macášek, Marek Vecka, Aleš Žák, et al.
Nutrition & Diabetes|September 11, 2024
Associations of plasma phospholipid cis-vaccenic acid with insulin resistance markers in non-diabetic men with hyperlipidemiaJaroslav Macášek, Barbora Staňková, Aleš Žák, et al.
Obesity Facts|February 23, 2013
Altered activities of antioxidant enzymes in patients with metabolic syndromeLucie Vávrová, Jana Kodydková, Miroslav Zeman, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|May 8, 2016
Chronic pancreatitis and the composition of plasma phosphatidylcholine fatty acidsMiroslav Zeman, Jaroslav Macášek, Michal Burda, et al.
Casopis Lekaru Ceskych|July 29, 2010
[Our experience with pancreatic cancer and its relation to diabetes mellitus]Tomás Krechler, Miroslav Zeman, Marek Vecka, et al.
The Tohoku Journal of Experimental Medicine|July 31, 2007
Severity of metabolic syndrome unfavorably influences oxidative stress and fatty acid metabolism in menAles Zák, Eva Tvrzická, Marek Vecka, et al.
Acta Pharmaceutica (Zagreb, Croatia)|October 18, 2016
Pleiotropic effects of niacin: Current possibilities for its clinical useMiroslav Zeman, Marek Vecka, František Perlík, et al.
Cancer Biomarkers : Section a of Disease Markers|June 18, 2016
Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitisJana Rychlíková, Marek Vecka, Marie Jáchymová, et al.
Pageof 4